0001500198 false 0001500198 2022-05-31 2022-05-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): May 31, 2022

 

NeuroOne Medical Technologies Corporation

(Exact name of registrant as specified in its charter)

 

Delaware   001-40439   27-0863354

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

 

7599 Anagram Dr., Eden Prairie, MN 55344

(Address of principal executive offices and zip code)

 

952-426-1383

(Registrant’s telephone number including area code)

 

(Registrant’s former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   NMTC   The Nasdaq Stock Market LLC

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging Growth Company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.07.  Submission of Matters to a Vote of Security Holders.

 

At the annual meeting (the “Annual Meeting”) of stockholders of NeuroOne Medical Technologies Corporation (the “Company”) on May 31, 2022, stockholders (i) elected one Class II director to the Company’s Board of Directors to serve a three-year term until the 2025 annual meeting of stockholders, and (ii) ratified the appointment of Baker Tilly U.S., LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2022. Proposals are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2022.

 

A total of 9,491,751 shares of the Company’s common stock were present at the meeting in person or by proxy, which represents approximately 58.62% of the shares of common stock outstanding as of the record date for the Annual Meeting.

 

The results of the voting are shown below:

 

Proposal 1—Election of Director

 

Class I Nominee   Votes For   Votes Withheld   Broker Non-Votes
David Rosa   4,552,178   411,044   4,528,529

 

Proposal 2—Ratification of Appointment of Independent Registered Public Accounting Firm

 

Votes For   Votes Against   Votes Abstain
9,421,086   44,729   25,936

 

Item 8.01 Other Events.

 

On June 2, 2022, NeuroOne Medical Technologies Corporation issued a press release providing a copy of the Annual Letter to Shareholders. A copy of this press release is filed herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.     Description
99.1   Press Release, dated June 2, 2022
104   Cover Page Interactive Data File (embedded with Inline XBRL document).

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  NEUROONE MEDICAL TECHNOLOGIES CORPORATION
Dated: June 2, 2022    
  By: /s/ David Rosa
    David Rosa
    Chief Executive Officer

 

 

2

 

 

NeuroOne Medical Technol... (NASDAQ:NMTC)
Historical Stock Chart
From Jan 2023 to Feb 2023 Click Here for more NeuroOne Medical Technol... Charts.
NeuroOne Medical Technol... (NASDAQ:NMTC)
Historical Stock Chart
From Feb 2022 to Feb 2023 Click Here for more NeuroOne Medical Technol... Charts.